How to Get Mounjaro in North Dakota

Mounjaro Basics: What Tirzepatide Does

Tirzepatide is a dual GIP/GLP-1 receptor agonist that targets two incretin pathways simultaneously [1]. The FDA approved it in May 2022 under the brand name Mounjaro for adults with type 2 diabetes [2]. Off-label prescribing for obesity has expanded rapidly since launch.

In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.58% at 40 weeks, compared with 1.86% for semaglutide 1 mg [1]. Weight loss in that same arm averaged 12.4 kg versus 6.2 kg with semaglutide. The magnitude of that difference caught the attention of endocrinologists and primary care providers across the country.

For weight management specifically, the SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks versus 2.4% with placebo [3]. Dr. Ania Jastreboff, the trial's principal investigator at Yale, stated: "These results represent a new era in the pharmacologic treatment of obesity" [3]. That trial formed the clinical backbone for Eli Lilly's separate obesity indication under the brand name Zepbound, approved in November 2023.

The drug works by slowing gastric emptying, enhancing insulin secretion in a glucose-dependent manner, and reducing appetite through central nervous system signaling [2]. Patients inject it once weekly, and the dose escalates from 2.5 mg to a maximum of 15 mg over several months.

North Dakota Telehealth Prescribing Rules

North Dakota law allows licensed providers to prescribe Mounjaro via telehealth. The state does not require an in-person visit before issuing a prescription for non-controlled substances like tirzepatide [4]. This makes access straightforward for patients in rural areas of the state, where endocrinology offices may be over 100 miles away.

Telehealth providers must hold an active North Dakota medical license or practice under a qualifying interstate compact. The North Dakota Board of Medicine recognizes the Interstate Medical Licensure Compact, which simplifies credentialing for out-of-state physicians [4]. Nurse practitioners in North Dakota have full practice authority under state law, meaning they can evaluate, diagnose, and prescribe independently without a collaborating physician agreement [5].

A typical telehealth visit for Mounjaro includes a medical history review, BMI assessment, discussion of prior weight-loss attempts, and lab ordering. Most platforms complete this process within 24 to 48 hours. The prescription then routes to a retail pharmacy or a licensed compounding pharmacy of the patient's choosing.

Patients in Bismarck, Fargo, Grand Forks, and Minot have access to local endocrinologists. But for residents in smaller communities like Williston, Dickinson, or Devils Lake, telehealth removes a barrier that previously required half-day drives for a single appointment.

Who Can Prescribe Mounjaro in North Dakota

Three categories of providers hold prescriptive authority for tirzepatide in North Dakota: physicians (MDs and DOs), nurse practitioners (NPs), and physician assistants (PAs).

North Dakota grants NPs full practice authority after completing a two-year, 2,000-hour supervised transition period [5]. After that threshold, NPs prescribe independently. This is relevant because many telehealth weight-loss platforms staff NPs as their primary clinicians. PAs in North Dakota prescribe under a collaborative agreement with a supervising physician, though the physician does not need to be physically present [5].

Any of these providers can write a Mounjaro prescription if they determine the patient meets clinical criteria. For type 2 diabetes, the threshold aligns with the FDA label: adults with type 2 diabetes as an adjunct to diet and exercise [2]. For off-label weight management, most providers follow the 2022 American Gastroenterological Association guideline, which recommends pharmacotherapy for patients with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity [6].

Board-certified obesity medicine specialists are available in Fargo through Sanford Health and in Bismarck through CHI St. Alexius, but no state regulation limits Mounjaro prescribing to specialists. Primary care providers write the majority of GLP-1 receptor agonist prescriptions nationally [7].

Labs and Medical Evaluation Before Starting

Standard pre-prescribing labs for Mounjaro include HbA1c, fasting glucose, a comprehensive metabolic panel (CMP), lipid panel, and thyroid-stimulating hormone (TSH) [2]. Providers order these to establish baseline metabolic status and rule out contraindications.

The FDA label carries a boxed warning about thyroid C-cell tumors based on rodent studies [2]. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). TSH alone does not screen for MTC, but it flags overt thyroid dysfunction that warrants further evaluation before initiating therapy.

A CMP checks kidney and liver function. Renal impairment does not require dose adjustment for tirzepatide, but severe hepatic impairment has not been studied [2]. Providers also assess for a history of pancreatitis, as GLP-1 receptor agonists have a theoretical association with acute pancreatitis, though large-scale data have not confirmed a causal link [8].

Most telehealth platforms accept labs drawn within the prior 90 days. If a patient does not have recent bloodwork, they can visit any Quest Diagnostics or Labcorp draw site in North Dakota, or use a local hospital lab. Results typically return within 1 to 3 business days.

Insurance and Cost in North Dakota

North Dakota Medicaid does not cover Mounjaro for weight loss. Coverage for the type 2 diabetes indication varies by managed care plan and may require step therapy through metformin first [9].

Commercial insurers in North Dakota, including Blue Cross Blue Shield of North Dakota (BCBSND) and Sanford Health Plan, may cover Mounjaro for type 2 diabetes with prior authorization. Weight-loss coverage under commercial plans remains inconsistent. BCBSND's 2025 formulary lists Mounjaro on a specialty tier with prior authorization required [9].

The cash price for brand-name Mounjaro runs approximately $1,000 to $1,100 per month without insurance. Eli Lilly's savings card program reduces the out-of-pocket cost to as low as $25 per fill for commercially insured patients, though this card does not apply to government insurance programs like Medicaid, Medicare, or Tricare [10].

Compounded tirzepatide through 503A pharmacies offers a lower-cost alternative, typically ranging from $300 to $500 per month depending on dose and pharmacy. This route requires a patient-specific prescription, and the compounding pharmacy must be licensed in the state to which it ships.

According to the Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity, "Cost remains a primary barrier to GLP-1 receptor agonist access, and clinicians should discuss all available pathways including manufacturer programs and compounding options with patients" [11].

Pharmacy Options: Retail, Mail-Order, and 503A Compounding

North Dakota patients have three pharmacy pathways for obtaining Mounjaro.

Retail pharmacies. Walgreens, CVS, and independent pharmacies across North Dakota can dispense brand-name Mounjaro with a valid prescription. Stock availability fluctuates. Patients should call ahead to confirm the specific dose strength is in stock, as supply shortages have affected certain pen strengths intermittently since 2023.

Mail-order pharmacies. Express Scripts, CVS Caremark, and OptumRx ship brand-name Mounjaro to North Dakota addresses. Mail-order often reduces per-unit cost for 90-day fills under commercial insurance. Delivery takes 3 to 5 business days via standard shipping; cold-chain packaging maintains the required 36°F to 46°F storage temperature during transit.

503A compounding pharmacies. North Dakota permits 503A compounding pharmacies to prepare and dispense tirzepatide based on individual patient prescriptions [12]. These pharmacies compound the drug from bulk tirzepatide powder and dispense it as reconstituted vials or pre-filled syringes. The FDA's current shortage list status for tirzepatide determines whether 503A compounding is permitted under federal law; providers and patients should verify this status at the time of prescribing [12].

503A pharmacies must hold a North Dakota Board of Pharmacy license to ship within the state. Out-of-state 503A pharmacies shipping to North Dakota patients must be licensed as non-resident pharmacies under N.D.C.C. § 43-15.3-12 [13].

Prior Authorization: What to Expect

Most commercial insurers in North Dakota require prior authorization (PA) before covering Mounjaro. The PA process typically takes 3 to 5 business days, though some plans offer electronic PA with 24-hour turnaround.

Documentation commonly required for PA includes: a confirmed diagnosis of type 2 diabetes (ICD-10 code E11.65 or related), current HbA1c value, BMI, a record of prior medication trials (often metformin for at least 90 days), and a letter of medical necessity from the prescribing provider [9].

For off-label weight-loss use, PA approval rates are lower. Some commercial plans categorically exclude anti-obesity medications. Patients denied coverage can file an internal appeal within 30 days, followed by an external review through the North Dakota Insurance Department if the internal appeal is denied [14].

The 2023 Treat and Reduce Obesity Act, if reauthorized, would require Medicare Part D to cover FDA-approved anti-obesity medications, but as of May 2026, this legislation has not been enacted into law.

Dosing Schedule and What to Expect

Mounjaro follows a structured dose-escalation protocol designed to minimize gastrointestinal side effects [2].

The starting dose is 2.5 mg injected subcutaneously once weekly for four weeks. This initial dose is for tolerability, not therapeutic effect. After four weeks, the dose increases to 5 mg weekly. If additional glycemic or weight control is needed, the provider may increase the dose in 2.5 mg increments every four weeks, up to a maximum of 15 mg weekly [2].

In SURPASS-2, the most common adverse effects were nausea (12% to 23% depending on dose), diarrhea (12% to 17%), and decreased appetite (5% to 11%) [1]. These side effects were most pronounced during dose escalation and typically subsided after 4 to 8 weeks at a stable dose.

Patients should inject Mounjaro in the abdomen, thigh, or upper arm, rotating injection sites weekly. The pen should be stored in the refrigerator at 36°F to 46°F. An unused pen can be kept at room temperature (up to 86°F) for up to 21 days [2].

Clinically meaningful weight loss, defined as ≥5% body weight reduction, typically appears by week 12 to 16 in patients on the 5 mg dose. In SURMOUNT-1 to 85% of participants on tirzepatide 5 mg achieved ≥5% weight loss at 72 weeks, compared with 35% on placebo [3].

Transferring a Prescription to North Dakota

Patients relocating to North Dakota or visiting for an extended period can transfer an existing Mounjaro prescription from another state. The receiving pharmacy in North Dakota contacts the originating pharmacy to complete the transfer. Federal law permits one transfer per prescription for non-controlled substances, and North Dakota follows this standard [13].

If the prescription originated from a telehealth provider licensed only in the patient's former state, a new prescription from a North Dakota-licensed provider will be necessary. Most telehealth platforms can re-establish care with a brief follow-up visit and order continuation without requiring new baseline labs if prior results are less than 6 months old.

Compounded tirzepatide prescriptions from out-of-state 503A pharmacies may also ship to North Dakota, provided the pharmacy holds nonresident licensure from the North Dakota Board of Pharmacy [13].

Safety Monitoring and Follow-Up

Ongoing monitoring while taking Mounjaro includes periodic HbA1c checks (every 3 to 6 months for diabetic patients), weight tracking, and symptom assessment for gastrointestinal tolerability [2].

Providers should monitor for signs of pancreatitis (severe abdominal pain radiating to the back), gallbladder disease (right upper quadrant pain after meals), and hypoglycemia when tirzepatide is combined with insulin or sulfonylureas [2]. The SURPASS clinical program reported gallbladder-related events in approximately 0.6% of tirzepatide-treated patients versus 0% on placebo [1].

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement recommends that patients on GLP-1 receptor agonists undergo at least quarterly follow-up during the first year of therapy, with assessments of body composition, metabolic markers, and medication adherence [15]. Telehealth visits satisfy this follow-up requirement in North Dakota.

Patients who achieve target weight loss face a clinical decision about continuation. Data from the SURMOUNT-4 trial showed that participants who discontinued tirzepatide after 36 weeks of treatment regained approximately 14% of lost body weight over the subsequent 52 weeks, compared with continued weight loss of 5.5% in those who stayed on the drug [16].